Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Full Track-and-Trace Anti-Counterfeiting Not Feasible, Industry Tells FDA

This article was originally published in The Gold Sheet

Executive Summary

The U.S. pharmaceutical industry is telling FDA that a full track-and-trace approach for following drugs through the supply chain is not the best way of dealing with the growing counterfeit problem. In the meantime, industry is devising a number of different approaches.
Advertisement

Related Content

Track-And-Trace: With Deadline a Year Away, Some Lessons from Early Adopters
Increased Awareness and Internal Programs Have Reduced Cargo Theft
Increased Awareness and Internal Programs Have Reduced Cargo Theft
In Brief
As Anti-Counterfeiting Approaches Diverge, Industry Calls for Harmonized Solutions
Advertisement
UsernamePublicRestriction

Register

PS000605

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel